Sotera Health/$SHC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sotera Health
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
- Ticker
- $SHC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Broadview Heights, United States
- Website
- soterahealth.com
Sotera Health Metrics
BasicAdvanced
$5.2B
32.00
$0.57
1.78
-
Price and volume
Market cap
$5.2B
Beta
1.78
52-week high
$19.85
52-week low
$13.09
Average daily volume
2M
Financial strength
Current ratio
2.796
Quick ratio
2.399
Long term debt to equity
3.373
Total debt to equity
3.407
Interest coverage (TTM)
3.34%
Profitability
EBITDA (TTM)
607.243
Gross margin (TTM)
54.97%
Net profit margin (TTM)
13.44%
Operating margin (TTM)
39.33%
Effective tax rate (TTM)
38.10%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
8.60%
Return on equity (TTM)
27.78%
Valuation
Price to earnings (TTM)
32.002
Price to revenue (TTM)
4.25
Price to book
7.78
Price to tangible book (TTM)
-7.44
Price to free cash flow (TTM)
45.857
Free cash flow yield (TTM)
2.18%
Free cash flow per share (TTM)
0.396
Growth
Revenue change (TTM)
8.15%
Earnings per share change (TTM)
570.85%
3-year revenue growth (CAGR)
7.60%
3-year earnings per share growth (CAGR)
-16.02%
What the Analysts think about Sotera Health
Analyst ratings (Buy, Hold, Sell) for Sotera Health stock.
Analyst projections of the future price of Sotera Health stock.
Bulls say / Bears say
Second-quarter revenue grew 8% on a constant-currency basis and adjusted EBITDA grew 8.7%; Sotera raised its full-year revenue and EBITDA growth outlook. That points to solid operating momentum across the business. (Sotera Health)
Sterigenics has several near-term growth drivers: a large customer is shifting sterilisation work from in-house to outsourced, and the new North Carolina X-ray facility is beginning to generate revenue. Management also expects another facility to open in early 2028. (Stock Analysis)
Net leverage fell to 3.0 times, the top of management’s target range, and available liquidity was about $950 million. Repricing its term loan is also expected to save roughly $3.5 million in annual interest costs. (Sotera Health)
Ethylene oxide litigation remains a potentially material uncertainty: the company disclosed around 150 personal-injury or wrongful-death claims in California, with initial trials scheduled for 2027, alongside hundreds of Georgia claims and ongoing appeals. Sotera says it cannot estimate the possible loss from future cases. (U.S. Securities and Exchange Commission)
Capital spending is high: Sotera forecast $200 million to $225 million in 2026 for facility upgrades, supply projects and expansion. Delays or cost overruns could weigh on cash generation before spending is expected to fall in 2027. (Sotera Health)
The company still carried $2.2 billion of debt at mid-year and expects $135 million to $142 million of interest expense in 2026. Even with leverage at its target ceiling, that debt burden limits room to absorb weaker trading or unexpected costs. (Sotera Health)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Sotera Health Financial Performance
Revenues and expenses
Sotera Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sotera Health News
AllArticlesVideos
Funds containing Sotera Health
AllUSDEURGBP
Fund name | Fund size | $SHC weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.15% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.15% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.07% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.07% |
iShares MSCI World Small Cap£WLDS | $9B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.